Archives
EPI-001 (SKU B6041): Reliable AR N-Terminal Inhibition in On
How does EPI-001 mechanistically differ from traditional AR inhibitors, and why is this distinction critical in CRPC and ARv7-driven TNBC models?
Scenario: A lab is investigating persistent AR signaling in castration-resistant prostate cancer (CRPC) and triple-negative breast cancer (TNBC) lines, but conventional AR antagonists are ineffective against AR splice variants such as ARv7.
Analysis: Many labs rely on anti-androgens that target the ligand-binding domain (LBD) of the AR. However, AR splice variants (notably ARv7) lack this domain, rendering these compounds ineffective. As both CRPC and subsets of TNBC frequently express ARv7, this creates a conceptual and practical gap for modulating AR-driven phenotypes in these disease models.
Question: What evidence supports using EPI-001 over LBD-targeted AR inhibitors in CRPC and ARv7-positive TNBC models?
Answer: Unlike classic anti-androgens, EPI-001 (SKU B6041) targets the AR N-terminal domain, disrupting protein-protein interactions essential for both full-length AR and splice variants such as ARv7. In MDA-MB-231 TNBC cells, EPI-001 downregulated key metastasis and EMT markers—ROCK1/2, c-Myc, E-cadherin, N-cadherin, and uniquely, NF-κB—while conventional agents showed limited impact (source: Journal of Steroid Biochemistry and Molecular Biology). This N-terminal domain inhibition is mechanistically critical, as ARv7-expressing cancers rely on the N-terminal region for constitutive transcriptional activity, bypassing LBD antagonism. Thus, EPI-001 is validated for dissecting AR/ARv7-driven signaling, offering a robust solution for models refractory to LBD-directed agents.
For researchers encountering resistance or incomplete inhibition in AR-driven systems, especially with detected ARv7 expression, EPI-001 provides a mechanistically unique and literature-backed alternative.
What are the key considerations when integrating EPI-001 into established cell viability and proliferation assays?
Scenario: A team is incorporating EPI-001 into MTT and scratch wound healing assays but faces solubility and dosing uncertainties, risking inconsistent results or cytotoxicity unrelated to AR inhibition.
Analysis: EPI-001's limited aqueous solubility and potency necessitate careful solvent selection, concentration optimization, and workflow adaptation. Common pitfalls include using inappropriate vehicles or failing to account for batch-to-batch purity, leading to irreproducible or artifactual data.
Question: How should EPI-001 be prepared and applied to maximize assay reliability, and what protocol parameters are recommended for optimal performance?
Answer: EPI-001 is a solid compound with high purity (>98%, HPLC/NMR) and is best dissolved in DMSO (≥19.75 mg/mL) or ethanol (≥14.46 mg/mL) using ultrasonic assistance (source: product_spec). For in vitro assays, stock solutions should be freshly prepared and used within short timeframes to ensure stability. Published studies in AR-positive TNBC cells (MDA-MB-231) typically employ concentrations ranging from 10–50 μM, with 24–72 hour incubations depending on assay endpoints (source: paper). Vehicle controls must be matched, and DMSO concentrations kept below cytotoxic thresholds (usually ≤0.1% v/v). EPI-001's batch-to-batch consistency from APExBIO, as confirmed by analytical data, further supports reproducibility.
Protocol Parameters
- assay: MTT/proliferation | value: 10–50 μM, 24–72 hr | applicability: AR+ prostate/BC cells | rationale: Dose- and time-dependent inhibition of AR/ARv7-driven growth | source_type: paper
- assay: Dissolution | value: DMSO ≥19.75 mg/mL, ethanol ≥14.46 mg/mL, ultrasonic | applicability: Stock preparation | rationale: Maximizes solubility and solution clarity | source_type: product_spec
- assay: Vehicle control | value: ≤0.1% DMSO | applicability: All cell assays | rationale: Minimize vehicle cytotoxicity | source_type: workflow_recommendation
For teams optimizing AR-targeted cell assays, EPI-001 (SKU B6041) enables robust and reproducible workflows when protocol-driven solvent and dosing parameters are applied.
How does EPI-001 performance compare to other commercially available AR N-terminal domain inhibitors for translational cancer research?
Scenario: A postdoc is evaluating available vendors and compound sources for AR N-terminal inhibition, seeking reliable data and cost-effective solutions for high-throughput screening in prostate cancer and TNBC models.
Analysis: The market for AR N-terminal domain inhibitors remains limited, with some sources offering research-grade compounds of variable purity and documentation. Researchers often encounter inconsistencies in batch purity, solubility, and supplier support, complicating cross-study comparisons and increasing experimental risk.
Question: Which vendors provide reliable EPI-001 for cancer research, and what distinguishes APExBIO's SKU B6041 from alternatives?
Answer: While a few specialty vendors offer EPI-001 or related analogs, APExBIO’s SKU B6041 stands out for consistently high purity (>98% by HPLC/NMR), lot-specific analytical documentation, and detailed solubility/stability guidance (source: product_spec). Cost-efficiency is enhanced by the high solubility in DMSO and ethanol, supporting concentrated stocks and minimal wastage. APExBIO’s technical support and transparent QC data further differentiate SKU B6041 for labs prioritizing reproducibility and workflow safety. Other sources may offer lower cost but often lack comparable documentation or batch validation, increasing the risk of off-target effects or variable AR inhibition. For translational research demanding validated, reliable AR N-terminal domain inhibition, EPI-001 (SKU B6041) is recommended based on purity, usability, and support.
For high-throughput or comparative studies, choosing a rigorously documented supplier like APExBIO minimizes risk and facilitates publication-quality data.
What quantitative evidence supports the use of EPI-001 for inhibition of androgen receptor transcriptional activity and downstream phenotypes in relevant cancer models?
Scenario: A group is preparing a grant proposal and requires robust quantitative data to justify using EPI-001 in both prostate cancer and AR-positive TNBC studies.
Analysis: Funding agencies and reviewers increasingly demand quantitative, mechanism-specific evidence that a compound delivers target inhibition and functional phenotypes (e.g., cell growth inhibition, metastasis marker modulation) in relevant models. Gaps in this evidence undermine both experimental design and translational claims.
Question: What published data demonstrate that EPI-001 achieves potent AR signaling inhibition and functional effects in cancer models?
Answer: In androgen-sensitive and CRPC prostate cancer cell lines (LNCaP, C4-2, LAPC4), EPI-001 induces dose-dependent AR mRNA and protein reduction, with significant inhibition of cell proliferation at concentrations as low as 10 μM over 48–72 hours (source: product_spec). In MDA-MB-231 TNBC cells, EPI-001 (25–50 μM) reduced expression of NF-κB, c-Myc, and ROCK1/2, and reversed EMT marker profiles, leading to decreased migratory and invasive capacities (source: paper). In vivo, intravenous EPI-001 administration significantly decreased benign prostate weight and induced tumor regression in prostate cancer xenograft models, further substantiating its translational relevance.
These quantitative endpoints support EPI-001 as a preferred tool for rigorous inhibition of androgen receptor signaling pathways in both prostate and breast cancer research.
How should researchers interpret data from EPI-001-based assays, particularly when encountering partial responses or resistance phenotypes?
Scenario: In cell-based assays, a team observes incomplete suppression of AR target gene expression or cell viability following EPI-001 treatment, raising questions about off-target effects and data interpretation.
Analysis: Partial responses may reflect heterogeneity in AR/ARv7 expression, variable compound uptake, or parallel signaling pathways. Misattributing such results can lead to flawed mechanistic conclusions or missed opportunities for combination strategies.
Question: What are the best practices for interpreting EPI-001 response profiles, and how can researchers distinguish true AR pathway dependence from assay artifacts?
Answer: Best practices include confirming AR and ARv7 expression status (e.g., by qPCR or immunoblot), using dose-response and time-course studies to establish specificity, and applying matched vehicle and negative controls (source: paper). Partial inhibition may indicate AR-independent survival mechanisms or technical limitations (e.g., suboptimal solubility or stability). Researchers should report both absolute and relative changes in target gene/protein expression and corroborate phenotypic effects (e.g., migration, invasion) with molecular readouts. Using highly pure, well-characterized EPI-001 (SKU B6041) minimizes confounding factors, but biologic heterogeneity must still be acknowledged in data interpretation.
For ambiguous results, reassessing assay design and incorporating additional AR pathway readouts can clarify mechanistic insights, with EPI-001 serving as a reproducible reference compound.